Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

icipated benefits of Senomyx's direct sales strategy; the anticipated timing and scope of commercial launch of products containing Senomyx's flavor ingredients, including S6973, S2383, S9632, S6821 and our Savory Flavors; whether the research under the Company's sweet taste research program, including ongoing safety studies and other regulatory-focused activities for S617, will be successful and lead to the commercialization of any new flavor ingredients or natural sweeteners; the progress and capabilities of Senomyx's discovery and development programs generally, including without limitation ongoing research to evaluate and potentially develop new Bitter Blockers and Cooling Agents, as well as our ability to identify proteins primarily involved in the perception of salt taste in humans. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx has no experience in manufacturing, marketing, or selling flavor ingredients on a commercial scale and may not successfully implement its direct sales strategy; Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's development revenues; Senomyx is currently dependent on its current and any future product discovery and development collaborators to develop, manufacture, and commercialize any flavor ingredients Senomyx may discover; Senomyx may not be able to establish new collaborations or other business arrangements and/or maintain existing collaborations on acceptable terms;  large companies are typically conservative when implementing changes to their branded products, and may not begin or expand their use of Senomyx flavor ingredients when expected or at all; development activities for newer flavor ingredients, including S617, may not demonstrate an acceptable safety profile or meet other commercialization criteria; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to
'/>"/>
SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Calif. , April 23, 2015  Cryoport, ... advanced cryogenic logistics solutions for the life sciences ... established its cryogenic logistics solutions within the animal ... with Yancey Farms to support the shipment of ... German Sport horse Stallions. Animal ...
(Date:4/23/2015)... Glemser Technologies is ... Enterprise Content Division (ECD) Certified Solution Partner to ... for Life Sciences Solution Suite . The accreditation ... to provide life sciences companies of all sizes ... EMC Documentum Solution Suite offers four modules: Quality ...
(Date:4/23/2015)... April 23, 2015  Propanc Health Group Corporation ... focuses on the development of cancer treatments for ... lead product includes PRP, a patented formulation consisting ... as well as the enzyme amylase designed to ... a combination of anti-cancer agents working in combination ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... 4, 2013 /Press Release/ Toxic waste sites with ... of "healthy years of life lost" in individuals living near ... a study by a Mount Sinai researcher published online today ... Kevin Chatham-Stephens, MD, Pediatric Environmental Health Fellow at the Icahn ...
... ON New research indicates that Mexican-Americans born in the ... significantly more likely than Mexican-American immigrants to report that ... physical activities such as walking, climbing stairs, reaching, lifting, ... in this week,s International Journal of Environmental Research ...
... 2, 2013 CDX Diagnostics, Inc ("CDX") and Shared ... patent infringement action against Histologics, LLC, Poplar HealthCare, PLLC ... Avero Diagnostics (collectively, "Defendants") in the United States District ... York . According to court documents, CDX and ...
Cached Biology News:Toxic waste sites cause healthy years of life lost 2Older US-born Mexican-Americans more physically limited than Mexican-American immigrants: Study 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Biology Products: